Company

Company

We improve the health and well-being of patients around the world.

Four business divisions united by a shared commitment to quality, safety and on-going innovation.

Commitment

Commitment

Patients inspire the work we do every day.

We support the development of the scientific community and its research efforts.

Innovation

Innovation

Take a look at the portfolio of products and therapies currently in development.

AMBAR, an ambitious research project on Alzheimer's.

AMBAR

AMBAR

Take a look at the information about the AMBAR study

The AMBAR trial results

Team

Team

We strive to cultivate a friendly, diverse and inclusive work environment.

Grifols is becoming increasingly global. A diverse team will remain a key component to our future success.

Products and services

INVESTORS

Latest news

05 nov, 2018 Bioscience Division revenues drive operational growth to 9.6% in the third quarter and boost net profits to Euros 468 million
Read more

27 oct, 2018 Grifols AMBAR results demonstrate a significant reduction in the progression of moderate Alzheimer's Disease
Read more

07 sep, 2018 Grifols and the European Investment Bank sign an Euros 85 million long-term loan to support its R+D+i initiatives
Read more

€4.3 billion

revenue

in 2017

20,000

employees

€311 million

in R+D+i investments

in 2017

Executive report

Corporate responsibility report

Contact

Av. de la Generalitat 152-158
Parc empresarial Can Sant Joan
08174 Sant Cugat del Vallès,
Barcelona – España
+34 93 571 02 21
investors@grifols.com

Subscribe to investors alerts

Subscribe to this service if you would like to receive by email the latest news for investors.

SUBSCRIBE UNSUBSCRIBE

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.